Medincell Appoints Edna Venneker, MD, as Chief Medical Officer

Experienced international pharmaceutical executive with a strong track record in clinical development, regulatory strategy, program execution and portfolio leadership

Former Head of Development and Senior Vice President at Grünenthal, with broad drug development experience across multiple therapeutic areas, including deep expertise in neuroscience and CNS disorders

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:

Medincell (Euronext: MEDCL), a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas, today announced the appointment of Edna Venneker, MD, as Chief Medical Officer.

Edna Venneker brings extensive international experience in drug development, spanning non-clinical and clinical strategy, regulatory affairs, program execution and portfolio decision-making. Most recently, she served as Head of Development and Senior Vice President at Grünenthal, where she oversaw clinical development, clinical operations, CMC, data science including pharmacometrics and Advanced Analytics. She also served as Deputy Chief Medical Officer and as a member of the R&D Leadership Team and the R&D Portfolio Board.

Throughout her career, Edna Venneker has led global, cross-functional development programs, advised biotechnology and pharmaceutical companies on development and regulatory strategies, and interacted directly with the FDA, EMA and PMDA across the drug development lifecycle. Her experience covers a broad range of therapeutic areas and product types, including small molecules, biologics, vaccines and advanced therapies.

“For long-acting injectable medicines, medical and regulatory strategy must be embedded from the very beginning of product design. Even more so than for conventional daily medicines, their development requires the close and simultaneous integration of clinical need, pharmacology, formulation, manufacturing, usability and regulatory considerations. This makes the role of the Chief Medical Officer both central and highly cross-functional.

I look forward to working with Medincell’s teams and with its current and prospective partners to evaluate opportunities, shape differentiated target product profiles and identify the most appropriate and efficient development and regulatory pathway for each program. Medincell’s technology creates the opportunity to rethink how proven medicines can address important unmet needs, and I am excited to help translate that potential into meaningful new treatment options for patients,” said Edna Venneker, MD, Chief Medical Officer of Medincell.

“Edna combines strategic vision with deep, hands-on experience across the full development lifecycle. Her ability to connect medical ambition, product design, regulatory strategy and execution will be invaluable as we expand our portfolio and deepen our collaborations with pharmaceutical partners. She joins Medincell at a pivotal stage, when our technology and growing development experience give us the opportunity to build the next generation of long-acting medicines. Her appointment strengthens our ability to select the most promising opportunities, reduce development risk and create sustainable value for patients, partners and shareholders,” said Christophe Douat, Chief Executive Officer of Medincell.

About Edna Venneker, MD

Before joining Medincell, Edna Venneker was Head of Development and Senior Vice President at Grünenthal, where she led functions spanning clinical development, clinical operations, CMC, data science and Pharmacometrics and Advanced Analytics. She previously served as Global Program Lead and Vice President at Grünenthal, with strategic and operational responsibility for a global Phase III development program and its cross-functional team.

Earlier in her career, she co-founded and served as Senior Partner of Afforce Healthcare, advising biotechnology and pharmaceutical companies on drug development, clinical development, medical affairs and regulatory strategy. She also acted as Chief Medical Officer and development leader for several biotechnology companies and programs, supporting projects from non-clinical development through clinical studies and regulatory submissions. Her previous positions include roles at Mundipharma Research, Pharming and Yamanouchi Europe, now Astellas.

Edna Venneker holds a medical degree from the Radboud University of Nijmegen in the Netherlands.

About Medincell

Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.

These treatments combine active pharmaceutical ingredients with our proprietary BEPO^® / BEPO^® Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable depot.

Risperidone LAI was the first treatment based on BEPO^® technology to receive FDA approval, initially for schizophrenia in April 2023 (one- and two-month dosing), and subsequently for Bipolar I Disorder in October 2025 (one-month dosing). It is marketed in the United States by Teva under the brand name UZEDY^®.

A New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment for schizophrenia in adults was submitted to the U.S. FDA in December 2025 by Medincell’s partner, Teva. U.S. FDA accepted Teva’s New NDA for Olanzapine LAI on February 20, 2026. A European Marketing Authorization Application (MAA) was also accepted by EMA in May 2026.

Medincell’s investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.

Headquartered in Montpellier, France, Medincell employs over 150 people representing more than 27 nationalities.

medincell.com

UZEDY^® is a trademark of Teva Pharmaceuticals. Medincell’s BEPO^® technology is licensed to Teva as SteadyTeq™, a trademark of Teva Pharmaceuticals.

This press release contains forward-looking statements, including statements regarding Company’s expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", “expect”, "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", “potential”, "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's universal registration document, filed with the AMF on July 29, 2025, under number D. 25-0580 (the "Universal Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 30 et seq. 26 of the Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions.